Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Rapper Fat Joe recently shared how he’s been using the Type 2 diabetes medication Ozempic to maintain his 200-pound weight ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...
Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
In response to rising demand for weight loss medications, WeightWatchers has launched a low-cost alternative to ...
When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback